The impact of metabolic dysfunction-associated steatotic liver disease on non-invasive fibrosis scores in patients with chronic hepatitis B: a multicenter retrospective study - PubMed
2 hours ago
- #Non-invasive Fibrosis Scores
- #Metabolic Dysfunction-Associated Steatotic Liver Disease
- #Chronic Hepatitis B
- MASLD status significantly affects the performance of non-invasive fibrosis tests (NITs) in patients with chronic hepatitis B (CHB).
- In MASLD-positive CHB patients, FIB-8 showed the highest AUROC (0.728) for predicting significant fibrosis, followed by Lok and ATA scores.
- In MASLD-negative CHB patients, FIB-4 had the highest AUROC (0.660), with FIB-8, Lok, and ATA scores performing worse.
- Overall, all NITs demonstrated low-to-moderate diagnostic accuracy, limiting standalone clinical use in CHB patients.
- The findings highlight the influence of metabolic factors on fibrosis markers and underscore the need for more accurate non-invasive models for this population.